Breakthrough cases and COVID-19 recovered individuals with one or two doses of vaccine have relatively higher protection against Delta variant in comparison to those administered either one or two doses of Covishield, a study stated.
Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response play an important role in protection, according to the study which is yet to be peer-reviewed and was posted on bioRxiv preprint server on Friday.
The study 'Neutralisation of Delta Variant with Sera of Covishield vaccines and COVID-19 Recovered Vaccinated Individuals' has been done by scientists from the Indian Council of Medical Research (ICMR), National Institute of Virology, Pune, and Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College, Pune.
The recent emergence of B.1.617 lineage has created grave public health problem in India.
The lineage further mutated to generate sub-lineages B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3. Apparently, the Delta variant has slowly dominated the other variants. With this, the World Health Organisation has described this sub-lineage as variant of concern, the study stated.
"The high transmissibility associated with Delta variant led to second wave of the pandemic in India which affected millions of people. Besides this, variant of concerns have been reported to show lower neutralisation to several approved vaccines. This has led to breakthrough infections after completion of vaccination regimen," it said.
There is limited information available on the duration of protective immune response post-infection, vaccination or breakthrough infection with SARS-CoV-2.
The study evaluated immune response in sera of the Covishield vaccinated individuals belonging to categories-- one dose vaccinated, two doses vaccinated, COVID-19 recovered plus one dose vaccinated, COVID-19 recovered plus two doses vaccinated and breakthrough COVID-19 cases.
"The findings of the study demonstrated that the breakthrough cases and COVID-19 recovered individuals with one or two dose of vaccine had relatively higher protection against Delta variant in comparison to the participants who were administered either one or two doses of Covishield.
"Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response play an important role in protection," the study added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)